−67%
Marketing cost reduction
+375%
Target results increase
7 → 1
US oncology category rank
Massive Bio operates at the frontier of oncology trial matching, where every marketing dollar has to do double duty — reaching patients and persuading institutions. The challenge: grow brand standing and conversion in a high-stakes, high-cost category without letting marketing spend spiral.
As CMO, Erkan Terzi ran Massive Bio's marketing economics using the very models that now power inMOLA — scoring the cost-to-conversion profile of every channel, pinpointing wasted spend, and reallocating budget toward channels with structural advantages.
Over twelve months, the company rose from 7th to 1st among seven major players in brand valuation within the U.S. cancer category, while marketing costs fell 67% and target results increased 375%. These results were produced with the same proprietary decision models that inMOLA delivers today as software — making this not a past consulting engagement, but live proof of the engine itself.